Macrocycles and Acyclic Cucurbitnurils as Pseudo2catenane Partners for Long-Acting Neuromuscular Blocks and Rapid Reversal In Vivo

• Published in: Journal of medicinal chemistry Vol. 67; no. 3; p. 2176
• Main Authors: Wu, Yan, Yang, Jingyu, Zhuang, Sheng-Yi, Yu, Shang-Bo, Zong, Yang, Liu, Yue-Yang, Wu, Gang, Qi, Qiao-Yan, Wang, Hui, Tian, Jia, Zhou, Wei, Ma, Da, Zhang, Dan-Wei, Li, Zhan-Ting
• Format: Journal Article
• Language: English
• Published: 08.02.2024
• ISSN: 1520-4804; 1520-4804
• DOI: 10.1021/acs.jmedchem.3c02110

Long-acting neuromuscular blocks followed by rapid reversal may provide prolonged surgeries with improved conditions by omitting repetitive or continuous administration of the neuromuscular blocking agent (NMBA), eliminating residual neuromuscular block and minimizing postoperative recovery, which, however, is not clinically available. Here, we demonstrate that imidazolium-based macrocycles (IMCs) and acyclic cucurbit[n]urils (ACBs) can form such partners by functioning as long-acting NMBAs and rapid reversal agents through a pseudo[2]catenation mechanism based on stable complexation with Ka values of over 109 M-1. In vivo experiments with rats reveal that, at the dose of 2- and 3-fold ED90, one IMC attains a duration of action corresponding to 158 or 442 min for human adults, covering most of prolonged surgeries. The block can be reversed by one ACB with recovery time significantly shorter than that achieved by sugammadex for reversing the block of rocuronium, the clinically most widely used intermediate-acting NMBA.Long-acting neuromuscular blocks followed by rapid reversal may provide prolonged surgeries with improved conditions by omitting repetitive or continuous administration of the neuromuscular blocking agent (NMBA), eliminating residual neuromuscular block and minimizing postoperative recovery, which, however, is not clinically available. Here, we demonstrate that imidazolium-based macrocycles (IMCs) and acyclic cucurbit[n]urils (ACBs) can form such partners by functioning as long-acting NMBAs and rapid reversal agents through a pseudo[2]catenation mechanism based on stable complexation with Ka values of over 109 M-1. In vivo experiments with rats reveal that, at the dose of 2- and 3-fold ED90, one IMC attains a duration of action corresponding to 158 or 442 min for human adults, covering most of prolonged surgeries. The block can be reversed by one ACB with recovery time significantly shorter than that achieved by sugammadex for reversing the block of rocuronium, the clinically most widely used intermediate-acting NMBA.